- |||||||||| Mavenclad (cladribine) / EMD Serono
Observational data, Journal: Therapeutic inertia in relapsing-remitting multiple sclerosis. (Pubmed Central) - Oct 22, 2021 TI is a topic rarely addressed in MS and this work highlights the importance of therapeutic optimization in these patients. Further studies should be held to explore the factors that influence TI once they have a great impact on therapeutic decisions.
- |||||||||| leflunomide / Generic mfg.
[VIRTUAL] WHEN TO LEAVE THE LEFLUNOMIDE () - Oct 13, 2021 - Abstract #CHEST2021CHEST_704; We describe the importance of recognizing some less commonly seen manifestations of LEF toxicity. Early discontinuation of LEF is key, and a cholestyramine washout should be performed if the clinical presentation is severe.
- |||||||||| Lemtrada (alemtuzumab) / Sanofi
[VIRTUAL] Psoriasis in Multiple Sclerosis Patients Treated with Disease Modifying Therapies () - Oct 8, 2021 - Abstract #CMSC2021CMSC_624; This observation is in line with reports from rheumatology and other medical fields where either de-novo psoriasis or exacerbation of known psoriasis have been observed in association with B cell depletion. Further research is needed to identify an actual excess risk and unravel the underlying immunopathologic mechanisms.
- |||||||||| Ponvory (ponesimod) / J&J
[VIRTUAL] MS Fatigue: Treatment Effect of Ponesimod in RMS Patients with and without Disease Activity () - Oct 8, 2021 - Abstract #CMSC2021CMSC_578; NNT itself is limited by clinical trial differences, and there is an increasing need to develop novel techniques to compare the efficacy of MS DMTs across clinical trials. Regardless of the EDA/NEDA status at week 108, ponesimod benefit over teriflunomide on MS- related fatigue remained the same, suggesting that addressing classical clinical efficacy (NEDA/EDA definition) might not be sufficient in addressing fatigue in RMS patients.
- |||||||||| Ponvory (ponesimod) / J&J
[VIRTUAL] Fatigue Evolution for Patients without Relapses on the Fsiq-RMS Symptoms Domain () - Oct 8, 2021 - Abstract #CMSC2021CMSC_536; These results are broadly consistent with the full analysis set which yielded a mean difference of -3.57 [95% CLs: ?5.83, ?1.32]; p=0.0019; favoring ponesimod 20mg relative to teriflunomide 14mg. The robustness and consistency of results in the change from baseline for patients without a confirmed relapse during the study relative to the full analysis set suggests a potential treatment effect for ponesimod on MS related fatigue independent of relapse activity.
- |||||||||| Kesimpta (ofatumumab subcutaneous) / Novartis, Genmab, Ponvory (ponesimod) / J&J, Lemtrada (alemtuzumab) / Sanofi
Journal: Ponesimod (Ponvory) for multiple sclerosis. (Pubmed Central) - Oct 7, 2021 Developing strategies to improve adherence remains important in longitudinal MS care. No abstract available
- |||||||||| Mavenclad (cladribine) / EMD Serono, Lemtrada (alemtuzumab) / Sanofi
Clinical, Journal: Effects of High and Low Efficacy Therapy in Secondary Progressive Multiple Sclerosis. (Pubmed Central) - Sep 29, 2021 In treated patients with SPMS, high-efficacy therapy is superior to low-efficacy therapy in reducing relapses in patients with active, but not those with inactive, SPMS. However, more potent therapies do not offer an advantage in reducing disability progression in this patient group.
- |||||||||| dimethyl fumarate / Generic mfg.
Clinical, Journal: Adherence to laboratory monitoring among people taking oral drugs for multiple sclerosis: A Canadian population-based study. (Pubmed Central) - Sep 26, 2021 Population-based health administrative and laboratory data were accessed in British Columbia, Canada, to identify everyone filling their first prescription for dimethyl fumarate (DMF), fingolimod or teriflunomide (2011-2015)...Adherence to recommended laboratory testing was high (>77%) before oral DMT initiation, but lower once on drug. There is a need to understand the long-term consequences of suboptimal laboratory monitoring and sex differences in the DMT-treated MS population.
- |||||||||| Lemtrada (alemtuzumab) / Sanofi
Review, Journal, HEOR: Disease modifying therapies in multiple sclerosis: cost-effectiveness systematic review. (Pubmed Central) - Sep 24, 2021 The present paper shows that cost-effectiveness studies have high levels of methodological variability, some of them reaching contradictory results. As a result, it is not possible to determine which disease- modifying therapy is really cost-effective in the context of relapsingremitting multiple sclerosis.
- |||||||||| Campath (alemtuzumab) / Sanofi, Lemtrada (alemtuzumab) / Sanofi
[VIRTUAL] Long-term immune-related adverse events after alemtuzumab (ePoster Library) - Sep 23, 2021 - Abstract #ECTRIMS2021ECTRIMS_2615; The autoimmune adverse events are probably related to immune dysregulation due to a differential lymphocyte repopulation following alemtuzumab. Autoimmune adverse events may be frequent, and it would be recommended to monitor its appearance in order to diagnose and treat them.
|